Skip to main content

Advertisement

SpringerLink
Log in

Pentraxin-3 is a candidate biomarker on the spectrum of severity from pre-eclampsia to HELLP syndrome: GenPE study

  • Article
  • Published:
Hypertension Research Submit manuscript

Abstract

Pentraxin-3 has been reported as a promising biomarker of pre-eclampsia and its severity; however, available studies have small sample sizes, and analyses are not always adjusted for confounders. The aim of this study is to establish the strength of the association between maternal Pentraxin-3 level and pre-eclampsia or HELLP syndrome. It was a case-control study. Women with pre-eclampsia or HELLP syndrome were defined as cases, and women with healthy pregnancies at term (>37 weeks) were classified as controls. Plasma concentrations of Pentraxin-3 were determined at the time of delivery by quantitative enzyme immunoassay. Associations between Pentraxin-3 and pre-eclampsia and HELLP syndrome were assessed by multinomial logistic regression. Subsidiary analysis for the time of disease onset was also carried out. Odds ratios and 95% confidence intervals are reported. A total of 1024 pregnant women were included (461 controls, 368 pre-eclampsia, 195 HELLP). A positive log-linear relationship was found between the top pentraxin-3 quintile and HELLP syndrome. After adjustment for confounders (maternal age, ethnicity, socioeconomic position, date and place of recruitment, family history of pre-eclampsia, smoking, body mass index at beginning of pregnancy, gestational age and multiple pregnancy), the strength of the association was higher for HELLP syndrome [OR 1.13 (95% CI 1.08; 1.18)] than for pre-eclampsia [OR 1.03 (95% CI 1.03; 1.10)]. No difference according to time of onset or pentraxin-3 level was found. In summary, pentraxin-3 level was associated with pre-eclampsia, but it was more strongly associated with HELLP syndrome. Longitudinal studies with a lower probability of residual confounding are necessary to improve our knowledge about the role of pentraxin-3 in pre-eclampsia.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Fig. 1
Fig. 2

Similar content being viewed by others

References

  1. Ronsmans C, Graham WJ. Maternal mortality: who, when, where, and why. Lancet. 2006;368:1189–200.

    Article  Google Scholar 

  2. Khan KS, Wojdyla D, Say L, Gülmezoglu AM, Van Look PF. WHO analysis of causes of maternal death: a systematic review. Lancet. 2006;367:1066–74.

    Article  Google Scholar 

  3. Abalos E, Cuesta C, Grosso AL, Chou D, Say L. Global and regional estimates of preeclampsia and eclampsia: a systematic review. Eur J Obstet Gynecol. 2013;170:1–7.

    Article  Google Scholar 

  4. Sibai B, Dekker G, Kupferminc M. Pre-eclampsia. Lancet. 2005;365:785–99.

    Article  Google Scholar 

  5. Levine R, Sachs BP, Epstein FH, Sibai BM, Sukhatme VP, Ph D. Circulating angiogenic factors and the risk of preeclampsia. N. Engl J Med. 2004;350:672–83.

    Article  CAS  Google Scholar 

  6. Borzychowski AM, Sargent IL, Redman CWG. Inflammation and pre-eclampsia. Semin Fetal Neonatal Med. 2006;11:309–16.

    Article  CAS  Google Scholar 

  7. Garlanda C, Bottazzi B, Bastone A, Mantovani A. Pentraxins at the crossroads between innate immunity, inflammation, matrix deposition, and female fertility. Annu Rev Immunol. 2005;23:337–66.

    Article  CAS  Google Scholar 

  8. Alles VV, Bottazzi B, Peri G, Golay J, Introna M, Mantovani A. Inducible expression of PTX3, a new member of the pentraxin family, in human mononuclear phagocytes. Blood. 1994;84:3483–93.

    Article  CAS  Google Scholar 

  9. Doni A, Peri G, Chieppa M, Allavena P, Pasqualini F, Vago L, et al. Production of the soluble pattern recognition receptor PTX3 by myeloid, but not plasmacytoid, dendritic cells. Eur J Immunol. 2003;33:2886–93.

    Article  CAS  Google Scholar 

  10. Muller B, Peri G, Doni A, Torri V, Landmann R, Bottazzi B, et al. Circulating levels of the long pentraxin PTX3 correlate with severity of infection in critically ill patients. Crit Care Med. 2001;29:1404–7.

    Article  CAS  Google Scholar 

  11. Fazzini F, Peri G, Doni A, Dell’Antonio G, Dal Cin E, Bozzolo E, et al. PTX3 in small-vessel vasculitides: an independent indicator of disease activity produced at sites of inflammation. Arthritis Rheum. 2001;44:2841–50.

    Article  CAS  Google Scholar 

  12. Jenny NS, Arnold AM, Kuller LH, Tracy RP, Psaty BM. Associations of pentraxin 3 with cardiovascular disease and all-cause death: the Cardiovascular Health Study. Arterioscler Thromb Vasc Biol. 2009;29:594–9.

    Article  CAS  Google Scholar 

  13. Zhou P, Luo X, Qi H-B, Zong W-J, Zhang H, Liu D-D, et al. The expression of pentraxin 3 and tumor necrosis factor-alpha is increased in preeclamptic placental tissue and maternal serum. Inflamm Res. 2012;61:1005–12.

    Article  CAS  Google Scholar 

  14. Tranguch S, Chakrabarty A, Guo Y, Wang H, Dey SK. Maternal pentraxin 3 deficiency compromises implantation in mice. Biol Reprod. 2007;77:425–32.

    Article  CAS  Google Scholar 

  15. Cetin I, Cozzi V, Pasqualini F, Nebuloni M, Garlanda C, Scd V, et al. Elevated maternal levels of the long pentraxin 3 (PTX3) in preeclampsia and intrauterine growth restriction. Am J Obstet Gynecol. 2006;3:1347–53.

    Article  Google Scholar 

  16. Rovere-Querini P, Antonacci S, Antonio GD, Angeli A. Plasma and tissue expression of the long pentraxin 3 during normal pregnancy and preeclampsia. Obstet Gynecol. 2006;108:148–55.

    Article  Google Scholar 

  17. Garg P, Kumar A, Kachhawa G, Kumar K. Estimation of asymmetric dimethylarginine (ADMA), placental growth factor (PLGF) and pentraxin 3 (PTX 3) in women with preeclampsia. Pregnancy Hypertens. 2018;14:245–51.

    Article  Google Scholar 

  18. Sibai BM. Diagnosis, controversies, and management of the syndrome of hemolysis, elevated liver enzymes, and low platelet count. Obstet Gynecol. 2004;103:981–91.

    Article  Google Scholar 

  19. Barton JR, Sibai BM. Diagnosis and management of hemolysis, elevated liver enzymes, and low platelets syndrome. Clin Perinatol. 2004;31:807–33.

    Article  Google Scholar 

  20. Roberts JM, Escudero C. The placenta in preeclampsia. Pregnancy Hypertens. 2012;2:72–83.

    Article  CAS  Google Scholar 

  21. Cozzi V, Garlanda C, Nebuloni M, Maina V, Martinelli A, Calabrese S, et al. PTX3 as a potential endothelial dysfunction biomarker for severity of preeclampsia and IUGR. Placenta. 2012;33:1039–44.

    Article  CAS  Google Scholar 

  22. Estudio de Genes Candidatos en Preeclampsia. 2005. Disponible en: www.genpe.org

  23. National High Blood Pressure Education Program. “Report of the national high blood pressure education program working group on high blood pressure in pregnancy”. Am J Obstet Gynecol. 2000;183:s1–22.

  24. Sibai BM. The HELLP syndrome (hemolysis, elevated liver enzymes, and low platelets): much ado about nothing? Am J Obstet Gynecol. 1990;162:311–6.

    Article  CAS  Google Scholar 

  25. Departamento Administrativo Nacional de Estadística. Estratificación Socioeconómica. 2019. Disponible en: https://www.dane.gov.co/files/geoestadistica/Preguntas_frecuentes_estratificacion.pdf.

  26. GenPE. Recruitment questionaire. 2010. Disponible en: http://www.genpe.org//index.php?option=com_content&task=view&id=41&Itemid=26.

  27. Papaioannou TG, Protogerou AD, Vrachatis D, Konstantonis G, Aissopou E, Argyris A, et al. Mean arterial pressure values calculated using seven different methods and their associations with target organ deterioration in a single-center study of 1878 individuals. Hypertens Res. 2016;39:640–7.

    Article  Google Scholar 

  28. Mantovani A, Garlanda C, Bottazzi B, Peri G, Doni A, Martinez Y. et al. The long pentraxin PTX3 in vascular pathology. Vascul Pharmacol. 2006;45:326–30.

    Article  CAS  Google Scholar 

  29. Peri G, Introna M, Corradi D, Iacuitti G, Signorini S, Pizzetti F, et al. PTX3, A prototypical long pentraxin, is an early indicator of acute myocardial infarction in humans. Circulation. 2000;102:636–41.

    Article  CAS  Google Scholar 

  30. Latini R, Maggioni AP, Peri G, Gonzini L, Lucci D, Mocarelli P, et al. Prognostic significance of the long pentraxin PTX3 in acute myocardial infarction. Circulation. 2004;110:2349–54.

    Article  CAS  Google Scholar 

  31. Carrizzo A, Procaccini C, Lenzi P, Fusco C, Villa F, Migliarino S, et al. PTX3: An inflammatory protein modulating ultrastructure and bioenergetics of human endothelial cells. Immun Ageing. 2019;16:3–7.

    Article  Google Scholar 

  32. Witasp A, Rydén M, Carrero JJ, Qureshi AR, Nordfors L, Näslund E, et al. Elevated circulating levels and tissue expression of Pentraxin 3 in uremia: a reflection of endothelial dysfunction. PLoS ONE. 2013;8:e63493.

    Article  CAS  Google Scholar 

  33. Fornai F, Carrizzo A, Forte M, Ambrosio M, Damato A, Ferrucci M, et al. The inflammatory protein Pentraxin 3 in cardiovascular disease. Immun Ageing. 2016;13:1–9.

    Article  Google Scholar 

  34. Benyo DF, Smarason A, Redman CWG, Sims C, Conrad KP, Obstetrics D, et al. Expression of inflammatory cytokines in placentas from women with preeclampsia. J Clin Endocrinol Metab. 2014;86:2505–12.

    Google Scholar 

  35. Rinehart BK, Terrone DA, Lagoo-deenadayalan S, William H, Hale EA, Martin JN, et al. Expression of the placental cytokines tumor necrosis factor α, interleukin 1 β, and interleukin 10 is increased in preeclampsia. Am J Obstet Gynecol. 1999;181:915–20.

    Article  CAS  Google Scholar 

  36. Pardi G. Diagnostic value of blood sampling in fetuses with growth retardation. Fetal Diagn Ther. 1993;328:601–2.

    Google Scholar 

  37. Cakmak HA, Cakmak BD, Yayla CA, Coskun I, Erturk M, Keles I. Hypertension in Pregnancy Assessment of relationships between novel inflammatory markers and presence and severity of preeclampsia: epicardial fat thickness, pentraxin-3, and neutrophil-to-lymphocyte ratio. Hypertens Pregnancy. 2017;36:233–9.

    Article  CAS  Google Scholar 

  38. Akolekar R, Casagrandi D, Livanos P, Tetteh A, Nicolaides KH. Maternal plasma pentraxin 3 at 11 to 13 weeks of gestation in hypertensive disorders of pregnancy. Prenat Diagn. 2009;29:934–8.

    Article  Google Scholar 

  39. Cetin I, Cozzi V, Papageorghiou AT, Maina V, Montanelli A, Garlanda C, et al. First trimester PTX3 levels in women who subsequently develop preeclampsia and fetal growth restriction. Acta Obstet Gynecol Scand. 2009;88:846–9.

    Article  CAS  Google Scholar 

  40. Höfler M. The Bradford Hill considerations on causality: a counterfactual perspective? Emerg Themes Epidemiol. 2005;2:11.

    Article  Google Scholar 

  41. Furuya K, Kumasawa K, Nakamura H, Nishimori K, Kimura T. Novel biomarker profiles in experimental aged maternal mice with hypertensive disorders of pregnancy. Hypertens Res. 2019;42:29–39.

    Article  CAS  Google Scholar 

  42. Hamad RR, Eriksson MJ, Berg E, Larsson A, Bremme K. Impaired endothelial function and elevated levels of pentraxin 3 in early-onset preeclampsia. Acta Obstet Gynecol Scand. 2012;91:50–6.

    Article  CAS  Google Scholar 

Download references

Funding

This work was supported by project grants from Departamento Administrativo de Ciencia, Tecnología e Innovación, Colciencias - Colombia [Grant number 14134319235]; and Universidad Autónoma de Bucaramanga - UNAB [Grant number EGEN22].

Author information

Authors and Affiliations

  1. Fundación Universitaria Sanitas, Bogotá, Colombia

    Claudia C. Colmenares-Mejía

  2. Research Centre, Fundacion Cardiovascular de Colombia (FCV), Bucaramanga, Colombia

    Claudia C. Colmenares-Mejía, Doris C. Quintero-Lesmes, Paula K. Bautista-Niño, Elizabeth Guio Mahecha & Norma Serrano Díaz

  3. Department of Obstetrics and Gynaecology, Universidad Industrial de Santander, Bucaramanga, Colombia

    Mónica Beltrán Avendaño

  4. Faculty of Health Sciences, Universidad Autónoma de Bucaramanga (UNAB), Bucaramanga, Colombia

    Mónica Beltrán Avendaño, Luis Alfonso Díaz Martínez, Ricardo Ortiz Serrano, María Carolina Páez Leal & María Lucrecia Luna

  5. Department of Pediatrics, Universidad Industrial de Santander, Bucaramanga, Colombia

    Luis Alfonso Díaz Martínez

  6. Public Health, Universidad Nacional de Colombia, Bogotá, Colombia

    María Carolina Páez Leal

  7. Department of Obstetrics and Gynaecology, Universidad de Cartagena, Cartagena, Colombia

    Álvaro Monterrosa Castro

  8. Department of Obstetrics and Gynaecology, Universidad CES, Medellín, Colombia

    Clara Maria Mesa Restrepo

  9. Clínica El Prado, Medellín, Colombia

    Germán Monsalve

  10. Department of Obstetrics and Gynaecology, Pontificia Universidad Boliviariana, Medellín, Colombia

    Enrique Sanín-Blair

  11. Department of Obstetrics and Gynaecology, Universidad del Valle, Cali, Colombia

    Wilmar Saldarriaga

  12. Massachusetts Veterans Epidemiology Research and Information Center (MAVERIC), VA Boston Healthcare System, Boston, MA, USA

    Juan P. Casas

Authors
  1. Claudia C. Colmenares-Mejía
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Doris C. Quintero-Lesmes
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Paula K. Bautista-Niño
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. Elizabeth Guio Mahecha
    View author publications

    You can also search for this author in PubMed Google Scholar

  5. Mónica Beltrán Avendaño
    View author publications

    You can also search for this author in PubMed Google Scholar

  6. Luis Alfonso Díaz Martínez
    View author publications

    You can also search for this author in PubMed Google Scholar

  7. Ricardo Ortiz Serrano
    View author publications

    You can also search for this author in PubMed Google Scholar

  8. María Carolina Páez Leal
    View author publications

    You can also search for this author in PubMed Google Scholar

  9. Álvaro Monterrosa Castro
    View author publications

    You can also search for this author in PubMed Google Scholar

  10. Clara Maria Mesa Restrepo
    View author publications

    You can also search for this author in PubMed Google Scholar

  11. Germán Monsalve
    View author publications

    You can also search for this author in PubMed Google Scholar

  12. Enrique Sanín-Blair
    View author publications

    You can also search for this author in PubMed Google Scholar

  13. Wilmar Saldarriaga
    View author publications

    You can also search for this author in PubMed Google Scholar

  14. María Lucrecia Luna
    View author publications

    You can also search for this author in PubMed Google Scholar

  15. Juan P. Casas
    View author publications

    You can also search for this author in PubMed Google Scholar

  16. Norma Serrano Díaz
    View author publications

    You can also search for this author in PubMed Google Scholar

Contributions

NSD and JPC are principal investigators who designed the GenPE study and led the idea for this paper. CCCM performed data analysis, interpretation and writing of the draft manuscript. DCQL and PKBN supported the data analysis and interpretation of the results. PBN and EGM performed sample analysis for pentraxin-3 measurements. MCPL was a national recruitment coordinator and made quality control of clinical information with LADM and MLL. MBN, ROS, AMC, CMR, GM, ESB, and WS were responsible for patient recruitment and data acquisition. All authors have made substantial contributions to the content of this paper and have read and approved the submission of the manuscript. The manuscript has not been published and is not being considered for publication elsewhere, in whole or in part, in any language.

Corresponding author

Correspondence to Claudia C. Colmenares-Mejía.

Ethics declarations

Conflict of interest

The authors declare that they have no conflict of interest.

Additional information

Publisher’s note Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.

Supplementary information

Rights and permissions

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Colmenares-Mejía, C.C., Quintero-Lesmes, D.C., Bautista-Niño, P.K. et al. Pentraxin-3 is a candidate biomarker on the spectrum of severity from pre-eclampsia to HELLP syndrome: GenPE study. Hypertens Res 43, 884–891 (2020). https://doi.org/10.1038/s41440-020-0434-0

Download citation

  • Received:

  • Revised:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1038/s41440-020-0434-0

  • Springer Nature Singapore Pte Ltd.

This article is cited by

Search

Navigation